GlassScriptPhysician profile
Ramya Varadarajan
NPI 1144450271
$900.69
in general payments reported to CMS, 2019-2025
22 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.00 · 2021: $25.81 · 2023: $24.96 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707 · Education: $72.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.15 |
| Education | $72.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $167.73 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $97.05 | 2025 | Opdivo |
| Incyte Corporation | $58.18 | 2025 | Jakafi, Niktimvo |
| Daiichi Sankyo INC. | $57.25 | 2025 | Enhertu |
| Beone Medicines USA, INC. | $54.29 | 2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $47.08 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $39.91 | 2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $38.68 | 2023-2025 | Calquence, Lynparza |
| Jazz Pharmaceuticals INC. | $33.38 | 2025 | |
| Merck Sharp & Dohme LLC | $32.30 | 2025 | Keytruda Qlex, Keytruda |
| Invivyd INC | $31.18 | 2025 | Pemgarda |
| Genzyme Corporation | $30.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.41 | 2025 | |
| Caris Mpi, INC. | $28.46 | 2025 | Mi Cancer Seek |
| Adaptive Biotechnologies Corporation | $26.74 | 2025 | Clonoseq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.50 | 2025 | Ojjaara |
| Genentech USA, INC. | $21.54 | 2025 | Polivy |
| Adc Therapeutics America, INC. | $20.00 | 2025 | |
| Pfizer INC. | $19.91 | 2025 | |
| Recordati_rare_diseases_inc. | $17.47 | 2025 | Enjaymo |
| Lilly USA, LLC | $13.89 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramya Varadarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.